Search
Tirzepatide Treatment Options in Iowa
A collection of 22 research studies where Tirzepatide is the interventional treatment. These studies are located in the Iowa, United States. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
13 - 22 of 22
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Offer
Lose Weight with Tirzepatide
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
Conditions:
Overweight
Overweight and Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Active Not Recruiting
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 2 Diabetes
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Completed
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Completed
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 2 Diabetes, Overweight, Obesity
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Completed
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: University of Iowa Hospital & Clinic, Iowa City, Iowa
Conditions: Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: University of Iowa Hospital & Clinic, Iowa City, Iowa +1 locations
Conditions: Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
Completed
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2019
Locations: Iderc P.L.C., West Des Moines, Iowa
Conditions: Type 2 Diabetes Mellitus
13 - 22 of 22